Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age-Reference-Cited by-同舟云学术

Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age

Published:2020-07 Issue:3 Volume:42 Page:231-236
ISSN:1110-1164
Container-title:The Egyptian Rheumatologist
language:en
Short-container-title:The Egyptian Rheumatologist

Author:

Alexeeva Ekaterina^ORCID,Dvoryakovskaya Tatyana,Denisova Rina,Sleptsova Tatyana,Isaeva Kseniya,Chomahidze Alexandra,Fetisova Anna,Mamutova Anna,Alshevskaya Alina,Moskalev Andrey

Publisher

Elsevier BV

Subject

Rheumatology

Reference27 articles.

1. Biologics in juvenile idiopathic arthritis: a narrative review;Vanoni;Eur J Pediatr.,2017

2. Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions;Shoop-Worrall;Lancet Child Adolesc Heal,2019

3. Early predictors of prognosis in juvenile idiopathic arthritis: A systematic literature review;Van Dijkhuizen;Ann Rheum Dis,2015

4. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study;Kearsley-Fleet;Rheumatology,2016

5. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis;Geikowski;Rheumatol (United Kingdom),2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leukocytoclastic vasculitis induced by adalimumab biosimilar in an elderly female with rheumatoid arthritis: A case-based review;The Egyptian Rheumatologist;2023-06